Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, announced eleven abstracts accepted for presentation at the American Association for Cancer Research Annual Meeting from April 14-19, 2023, in Orlando, FL. The abstracts will showcase advancements in the company’s antibody drug conjugates, multispecific antibodies, and clinical candidates, including ZW171 and ZW191. The management team will host a conference call on April 18, 2023, at 6:30 pm EST to discuss these developments. The abstracts reflect Zymeworks' commitment to pioneering treatments for difficult-to-treat cancers.
- None.
- None.
- Eleven abstracts accepted for poster presentation highlight company’s differentiated antibody drug conjugate, multispecific antibody, and clinical product candidates
-
Management will host a conference call on
April 18 th at6:30 pm Eastern Standard Time (EST)
“AACR represents an important opportunity for us to share recent progress in developing the next generation of novel therapeutics and highlights the unique capabilities of our proprietary engineering platforms and integrated technologies,” stated
Presentation Details
Antibody Drug Conjugates
Title: Revisiting the dogma of antibody drug conjugates (ADCs): Emerging data challenge the benefit of linker stability and the primacy of payload delivery
Abstract: 1538
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Drug Conjugates
Title: ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
Abstract: 2641
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies
Title: ZW220, a novel NaPi2b-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
Abstract: 1533
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Drug Conjugates
Title: ZW251, a novel glypican-3-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload
Abstract: 2658
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies
Multispecific Antibody Therapeutics
Title: ZW171, a T cell-engaging, bispecific antibody for the treatment of mesothelin-expressing solid tumors
Abstract: 2942
Session Category: Immunology
Session Title: Therapeutic Antibodies 2
Title: TriTCE Co-stim, next generation costimulatory trispecific T cell engagers for the treatment of solid tumors
Abstract: 5121
Session Category: Immunology
Session Title: Combination Immunotherapies 2
Title: TriTCE CPI, next generation trispecific T cell engagers with integrated checkpoint inhibition (CPI) for the treatment of solid tumors
Abstract: 2982
Session Category: Immunology
Session Title: Therapeutic Antibodies 3
Title: PROTECT™, a novel trispecific antibody masking platform with integrated immune modulation displays unique activity and differentiated modes of action
Abstract: 2926
Session Category: Immunology
Session Title: Therapeutic Antibodies 2
Title: ZW270, a conditionally masked IL-12 cytokine fusion protein displaying potent anti-tumor activity absent systemic toxicity
Abstract: 2935
Session Category: Immunology
Session Title: Therapeutic Antibodies 2
Clinical Product Candidates
Title: ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a phase 1, study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Abstract: CT2781
Session Category: Clinical Trials Posters
Session Title: Phase I Clinical Trials 2
Title: Zanidatamab zovodotin (ZW49) induces hallmarks of immunogenic cell death and is active in patient-derived xenograft models of gastric cancer
Abstract: 2633
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody Technologies
Abstracts can be found on AACR’s website located at www.aacr.org. Posters will be available at the time of presentation at the conference on the Company's website located at www.zymeworks.com.
1 Clinical trials abstract texts are embargoed until |
Conference Call and Webcast Information:
About
Cautionary Note Regarding Forward-Looking Statements
This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ preclinical pipeline; the potential therapeutic effects of zanidatamab and Zymeworks’ other product candidates; Zymeworks’ clinical development of its product candidates and enrollment in its clinical trials; anticipated preclinical and clinical data presentations; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as “plan”, “believe”, “expect”, “may”, “anticipate”, “potential”, “will”, “continues”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions.
Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: future clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; clinical trials may not demonstrate safety and efficacy of any of Zymeworks’ or its collaborators’ product candidates; any of Zymeworks’ or its partners’ product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of the COVID-19 pandemic on Zymeworks’ business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf, may be more severe and more prolonged than currently anticipated; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under “Risk Factors” in Zymeworks’ quarterly and annual reports filed with the
Although
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005744/en/
Investor Inquiries:
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Source:
FAQ
What is Zymeworks Inc. announcing regarding the AACR Annual Meeting?
When will Zymeworks hold a conference call to discuss the AACR presentations?
What types of candidates are being presented by Zymeworks at the AACR meeting?
What are ZW171 and ZW191?